Mural Oncology initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Mural Oncology (MURA) with a Buy rating and $16 price target Mural is developing cytokine therapies for cancer patients, the analyst tells investors in a research note. The firm says the company’s lead asset is a “highly differentiated” IL-2 fusion protein that blocks adverse event causing complex formation, stops proliferation of immune dampening T cell types and activates tumor killing NK and T cells.